Clinical use of Letrozole is described in this record across HR-positive breast cancer in postmenopausal patients, including advanced/metastatic and adjuvant settings. The medicine belongs to the nonsteroidal aromatase inhibitor class and is categorized as Hormonal / Endocrine Therapy; Aromatase Inhibitor. The entry emphasizes a nonsteroidal aromatase inhibitor used in postmenopausal HR-positive breast cancer, including adjuvant and advanced or metastatic settings and combinations with CDK4/6 inhibitors. Suppresses estrogen production by inhibiting aromatase. The therapeutic effect is tied to estrogen or other hormone signaling, so receptor status, menopausal context, and disease setting help define its place in treatment. Breast Cancer are the associated tumor types listed in the database. Its regimen field includes Letrozole monotherapy; letrozole + CDK4/6 inhibitor; adjuvant endocrine therapy. The range of combinations reflects disease-specific treatment design: the appropriate partner and treatment position depend on the malignancy and the indication being addressed. The database places it within endocrine management, where the hormonal environment and disease state are important determinants of clinical use. When a molecular alteration, receptor profile, disease stage, or prior-treatment condition is explicitly included, it should not be separated from the indication itself. Those details help distinguish the medicine’s intended role from broader statements about its drug class. Regulatory labeling and disease-specific guidelines should be reviewed for current clinical use.